University of Amsterdam

Slides:



Advertisements
Similar presentations
Introduction Michael de la Christopher Parlette Brian Ari
Advertisements

Continuous Glucose Monitoring
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.
DEPARTMENT OF COUNSELLING
Suhyla Alam (Eastern Virginia Medical School), Amy West, Maura Downey, Jane EB Reusch, Kristen Nadeau University of Colorado Denver and Children’s Hospital.
Practical Aspects of Continuous Glucose Monitoring 2008 Rosanna Fiallo-Scharer, MD Laurel Messer, RN, BSN, CDE Barbara Davis Center for Childhood Diabetes.
Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes The TODAY clinical trial Featured Article: TODAY Study Group* Diabetes Care Volume.
Abstract Background: As part of a study to evaluate the accuracy of the GlucoWatch ® G2 TM Biographer and the Continuous Glucose Monitoring System (CGMS.
Diabetes Research in Children Network Pilot Study of the Navigator TM Continuous Glucose Monitoring System in Children with Type 1 Diabetes: Safety, Tolerability,
Ohara C ( Mph ), Murata A ( MD ), Inoue M ( MD,PhD ), Inoue K ( MD,PhD ) Persons with undiagnosed diabetes have worse profiles of cardiovascular and metabolic.
Needle-Free Diabetes Care Josiah Riggins. Back Ground  2 Types of Diabetes  Insulin Key Hormone  Diabetes can be fatal and will be over time if there.
Use of The FreeStyle Navigator TM Continuous Glucose Monitoring System in Children on Glargine- based Multiple Daily Injection Therapy Stuart Weinzimer.
Continuous Glucose Monitors
Effectiveness of Early Intensive Therapy On β-Cell Preservation in Type 1 Diabetes Featured Article: Bruce Buckingham, M.D., Roy W. Beck, M.D., P.H.D.,
The Diabetic Retinopathy Clinical Research Network Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control (Protocol M) 11.
Retinopathy in Youth With Type 2 Diabetes Participating in the TODAY Clinical Trial Featured Article: TODAY Study Group* Diabetes Care Volume 36:
The Physiological Variations of Plasma Glucose Concentrations in Healthy, Non-Diabetic Children: Use of Continuous Glucose Sensors Nelly Mauras, Roy Beck,
Dr Zaranyika MBChB(Hons) UZ, MPH, FCP SA Department of Medicine UZ-CHS
 History of advancement in diabetes treatment  New technology  Features  Pros and Cons  Safety in school  Questions.
analysed to establish the distribution of GJD2 SNPs   T2D patients
Teddy Ryder, 5yrs, 12.5 kg (1922) Teddy Ryder (1923) Dr. Best & Dr. Banting.
GLOBAL CONTINUOUS GLUCOSE MONITORING (CGM) MARKET - Opportunity Analysis on the basis of Product, End Use, Geography, Industry Forecast 2025
Galen College of Nursing Gabriela Morris NUR 3150 Dr. Marion Johnson
Use of the Estimated Average Glucose (eAG) in Patient Care
Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,
Baseline characteristics
ADVERSE OUTCOMES OF TREATING HIV-TB
New Innovations in Diabetes Technology
*Imperial College London
Key publication slides
Alcohol, Other Drugs, and Health: Current Evidence
User innovation COUCHING SESSION 2
Without insulin therapy (n = 14)
Osborne K.B., Davies S.J., Coppini D.V.
Balloon-pump assisted Coronary Intervention Study (BCIS-1):
FreeStyle Libre Glucose Monitoring System
Sensor Procedure Conducted by Senseonics Clinical Training Manager (CTM) At least 2 doctors plus nurses Conducted same day as first patient insertion About.
Lifestyle and Professional CGM
Sensor – inserted in upper arm (this is only indication in the labeling). All biocompatible materials. Outer capsule material is made of same material.
Today we are going to cover….
Clinical Performance.
Battery life of transmitter is a minimum of 6 months.
Components of a CGM record over a 3
LBL Rev 01.
Prediabetes Screening and Monitoring
Today we are going to cover….
A review of the new Eversense CGM System
Are cardiac rehabilitation patients meeting the physical activity guidelines 12-months after their event? a longitudinal study Dr Nicole Freene Ms Margaret.
Study Objective & Methods
A DIGITAL, END-TO-END, NATIONWIDE, PRAGMATIC TRIAL OF SCREENING FOR UNDIAGNOSED ATRIAL FIBRILLATION: PRIMARY RESULTS OF THE mSToPS TRIAL Steven R. Steinhubl,
Faster-Acting Insulins
Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53
Self-collection Of Stool: An Alternative To Digital Rectal Examination For Fecal Occult Blood Testing In The Emergency Department P. B. Lovett, J. D. D'Angelo,
DiRECT (Diabetes Remission Clinical Trial)
Emily Gilbert, Lisa Calderwood
Clinical outcome after SVR: ANRS CO22 HEPATHER
Presenter #1 • Presenter #2 • Presenter #3 Presenter #4 • Presenter #5
Structure Starting with a needs assessment Research training Research workstream project selection Nine workstreams Automated forensic analysis Image.
Strip me.
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
Concetta Irace Department of Health Science
Fig.1. The dose of GH administered to patients in different age groups after 1 year of GH replacement therapy. Data are shown as mean, median and 10th-90th.
Latent TB Infection among Diabetic patients
Campbell FM, et al. Pediatr Diabetes. 2018;19(7):1294–1301
Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD
Atlantic Cardiovascular Patient Outcomes Research Team
Incidence of HCC after HCV treatment with DAAs: ERCHIVES
Trajectories over the 9 years of follow-up of HbA1c in all participants (n = 4,080 at baseline), stratified by the presence of a family history of diabetes,
Progression to micro- or macroalbuminuria.
Sodium consumption (mg/day) at baseline by demographic characteristics in a cohort of self-referred patients with type 2 diabetes. Sodium consumption (mg/day)
Presentation transcript:

University of Amsterdam The `PRECISE´ Study Senseonics implantable CGM PART 1 | Accuracy and lifetime PART 2 | Experience from German patients University of Amsterdam University of London University of Cambridge PI: J. Kropff / J. H. DeVries PI: P. Choudhary PI: R. Hovorka Swansea University Profil Mainz Profil Neuss University of Ulm Senseonics Incorporated 1 PI: S.C. Bain PI: C. Kapitza, T. Forst PI: M. Link

Study objective Investigate the accuracy of the Eversense CGM System up to 180 days

Participant Baseline Characteristics 3-month cohort (n= 71) Age (years) 41.7 ± 12.6 Sex, male (n)(%) 42 (59.2%) BMI (kg/m2) 27.0 ± 4.2 Diabetes duration (years) 22.2 ± 12.5 HbA1c (%) 7.6 ± 1.1 Insulin pump users (n)(%) CGM user before study (n)(%) 32 (45.1%) ± SD

Accuracy throughout 90-day period MARD (days 0-90) 11.5% MARD (%)

Lifetime of the sensors 90 days, 88%

Accuracy of the sensor A: 84.8% B: 14.5% C: 0.0% D: 0.7% E: 0.0%

HbA1c improvement 0.5%(percent points) HbA1c-decrease from day 0 to day 90

Transmitter Wear Compliance Wear Compliance (hours/day) 71 Enrolled subjects Median Wear Time: 23.5 Hours/Day 25th Percentile: 22.0 Hours/Day

Conclusions (Part 1) Successful study with an implantable CGM system The system measures glucose accurately and reliably during up to 90 days The results are similar or better than other CGM- Systems already in the market Data from the 6-months analysis available soon

Part 2 | PRECISE Study Experience from German patients University of Amsterdam University of London University of Cambridge Swansea University University of Ulm Profil Mainz Profil Neuss 06. März 2016

Patient Feedback from the PRECISE Study After 90 days patients were asked to share their experiences with the usage of the system

month day, year Implantation in 5-minute procedure At the doctor‘s office under local anesthesia 1. Make Incision 2. Insert Sensor 3. Cover Incision 5 to 8 mm Incision made in Upper Arm (Lidocaine) Sensor Inserted with Custom Inserter Steri-Strips™ to Close Sensor holder Sensor holder frame Sensor Insertion tools The sensor is replaced after 90 days The transmitter can be taken off/put back on (for example, when swimming, bathing, etc.) HEADER AND FOOTER: INSERT > HEADER AND FOOTER

Patient Feedback Implantation and pain `The sensor insertion was painless´  90% - Yes, I agree!  3% - Neither agree nor disagree  8% - No, I disagree!

Infections Altogether 166 sensors were inserted in the PRECISE study Three patients had local infections 2 after insertion (1.2 %) 1 after removal One infection had to be treated and the sensor was removed

Scars

The Transmitter 4.0 x 3.8 x 1.3 cm

Patient Feedback Transmitter `The transmitter was comfortable to wear´  78% - Yes, I agree!  3% - Neither agree nor disagree  20% - No, I disagree

Mobile App

Patient Feedback Low/high glucose alarm `The alarms warned me of low/high glucose´  95% - Yes, I agree!  3% - Neither agree nor disagree  3% - No, I disagree!

Patient Feedback “Deutlich weniger Hypos durch eine frühzeitige Warnungmehr Sicherheit Lebensqualität!!!! Ich mache jetzt viel mehr Sport” Eversense CGM System

Doing now what patients need next